(NASDAQ: MTSR) Metsera's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 39.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.26%.
Metsera's earnings in 2025 is N/A.On average, 6 Wall Street analysts forecast MTSR's earnings for 2025 to be -$325,220,429, with the lowest MTSR earnings forecast at -$358,281,407, and the highest MTSR earnings forecast at -$231,647,461. On average, 6 Wall Street analysts forecast MTSR's earnings for 2026 to be -$390,050,201, with the lowest MTSR earnings forecast at -$406,669,988, and the highest MTSR earnings forecast at -$366,223,605.
In 2027, MTSR is forecast to generate -$477,120,231 in earnings, with the lowest earnings forecast at -$514,772,136 and the highest earnings forecast at -$415,862,347.